---
figid: PMC7251113__41598_2020_65450_Fig1_HTML
figtitle: Proposed mechanism of synergy of co-encapsulated vitamin E succinate modified
  octahistidine-octaarginine (VES-H8R8) and palmityl-doxorubicin (pDOX)
organisms:
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7251113
filename: 41598_2020_65450_Fig1_HTML.jpg
figlink: pmc/articles/PMC7251113/figure/Fig1/
number: F1
caption: Schematic representation of the proposed mechanism of synergy of co-encapsulated
  vitamin E succinate modified octahistidine-octaarginine (VES-H8R8) and palmityl-doxorubicin
  (pDOX). (i) Structure of poly(D,L-lactide-co-2-methyl-2-carboxytrimethylenecarbonate)12K-g-poly(ethylene
  glycol)10K (P(LA-co-TMCC)-g-PEG) used as amphiphilic polymer for NP synthesis. (ii)
  Structure of vitamin E succinate modified octahistidine-octaarginine (VES-H8R8),
  with vitamin E succinate in red and octahistidine-octaarginine in blue. (iii) Structure
  of the pH-responsive, palmityl-doxorubicin (pDOX), with doxorubicin in pink, palmityl
  moiety in green, and the pH-responsive hydrazone bond in black. VES-H8R8 and pDOX
  loaded NPs (VDNPs) enter cells through the endolysosomal pathway where VES-H8R8
  and hydrolyzed pDOX escape into the cytosol. VES-H8R8 affects the mitochondria and
  decreases the mitochondrial membrane potential. VES-H8R8 inhibits the permeation
  glycoprotein (Pgp) efflux of Dox, allowing the cytosolic accumulation of Dox. Accumulated
  Dox poisons topoisomerase II and, together with VES-H8R8, synergistically kills
  multi-drug resistant breast cancer cells.
papertitle: Nanoparticle delivery of a pH-sensitive prodrug of doxorubicin and a mitochondrial
  targeting VES-H8R8 synergistically kill multi-drug resistant breast cancer cells.
reftext: Petro Czupiel, et al. Sci Rep. 2020;10:8726.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.697449
figid_alias: PMC7251113__F1
figtype: Figure
redirect_from: /figures/PMC7251113__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7251113__41598_2020_65450_Fig1_HTML.html
  '@type': Dataset
  description: Schematic representation of the proposed mechanism of synergy of co-encapsulated
    vitamin E succinate modified octahistidine-octaarginine (VES-H8R8) and palmityl-doxorubicin
    (pDOX). (i) Structure of poly(D,L-lactide-co-2-methyl-2-carboxytrimethylenecarbonate)12K-g-poly(ethylene
    glycol)10K (P(LA-co-TMCC)-g-PEG) used as amphiphilic polymer for NP synthesis.
    (ii) Structure of vitamin E succinate modified octahistidine-octaarginine (VES-H8R8),
    with vitamin E succinate in red and octahistidine-octaarginine in blue. (iii)
    Structure of the pH-responsive, palmityl-doxorubicin (pDOX), with doxorubicin
    in pink, palmityl moiety in green, and the pH-responsive hydrazone bond in black.
    VES-H8R8 and pDOX loaded NPs (VDNPs) enter cells through the endolysosomal pathway
    where VES-H8R8 and hydrolyzed pDOX escape into the cytosol. VES-H8R8 affects the
    mitochondria and decreases the mitochondrial membrane potential. VES-H8R8 inhibits
    the permeation glycoprotein (Pgp) efflux of Dox, allowing the cytosolic accumulation
    of Dox. Accumulated Dox poisons topoisomerase II and, together with VES-H8R8,
    synergistically kills multi-drug resistant breast cancer cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HRG
  - NRG1
  - SLC48A1
  - MANEA
  - ROS1
  - PGP
  - ABCB1
  - PGPEP1
  - rg
  - hrg
  - Np
  - EndoA
  - Mdr65
---
